Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from a Phase Ib clinical study of its drug ABSK021 (pimicotinib) in the treatment of tenosynovial giant cell tumor (TGCT) at the American Society of Clinical Oncology (ASCO) annual meeting.

Impressive Objective Response Rates for Pimicotinib
The study reported an objective response rate (ORR) of 77.4% (24/31) for the 50mg QD dose group of pimicotinib (ABSK021), which includes 2 complete responses (CR) and 22 partial responses (PR). Notably, an objective response was observed in 87.5% (21/24) of patients within the first 25 weeks of treatment. These figures indicate a significant therapeutic potential for pimicotinib in TGCT, a disease for which there is currently no approved drug in China.

Safety and Tolerability of Pimicotinib
In addition to its efficacy, pimicotinib (ABSK021) demonstrated significant advantages in terms of safety and tolerability, which are critical factors in the treatment of TGCT. This is in contrast to pexidartinib, the only TGCT drug globally developed by Daiichi Sankyo, which carries a black box warning in the US due to the risk of potentially lethal liver damage and has an ORR of 38%.

Global Phase III Study for Pimicotinib in TGCT
Abbisko has previously initiated a global Phase III study for pimicotinib in TGCT in China, aiming to enroll 100 subjects across 30 centers in China and 50 worldwide. This study is a testament to the company’s commitment to advancing the treatment of TGCT and bringing a much-needed therapy to patients globally.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry